LC, a novel estrone-rhein hybrid compound, promotes proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells

Molecular and Cellular Endocrinology

Volumn 344, Issue 1-2, 2011, Pages 59-68

  Wang, Yue ^a,b   Li, Ling Zhi ^a,b   Zhang, Yong Liang ^b   Sun, Wei Jia ^a   Zhu, Ya Qin ^a   Cui, Ying ^a   Qi, Lin ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b Tianjin Key Laboratory for Biomarkers of Occupational and Environmental Hazard   (China)

Author keywords

Differentiation; LC; Osteoblast; Proliferation; Survival

Indexed keywords

CISPLATIN; DOUBLE STRANDED RNA; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FULVESTRANT; HYBRID COMPOUND LC; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RHEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BONE MINERAL; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM; ESTROGEN RESPONSIVE ELEMENT; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALKALINE PHOSPHATASE; ANTHRAQUINONES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLLAGEN; ENZYME ASSAYS; ESTROGENS; ESTRONE; GENE EXPRESSION; HUMANS; NUCLEAR RECEPTOR COACTIVATOR 3; OSTEOBLASTS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84860396132     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.06.027     Document Type: Article

References (55)

1. Bauss F., Esswein A., Reiff K., Sponer G., Müller-Beckmann B. Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats. Calcif. Tissue Int. 1996, 59:168-173.
2. Boileau C., Tat S.K., Pelletier J.P., Cheng S., Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodeling. Arthritis Res. Ther. 2008, 10:R71.
3. Bynoe M., Grimaldi C., Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells. Proc. Natl. Acad. Sci. 2000, 7:2703-2708.
4. Chen J.R., Haley R.L., Hidestrand M., Shankar K., Liu X., Lumpkin C.K., Simpson P., Badger T., Ronis M. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-κB ligand in osteoblasts. J. Pharm. Exp. Ther. 2006, 319:1182-1190.
5. Choi K., Kang S., Tai C., Auersperg N., Leung P. Estradiol up-regulates anti-apoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 2001, 142:2351-2360.
6. Cui Y., Li L.Z., Zhu J. Determination of rhein in mouse bone by HPLC. Chin. J. New Drugs 2008, 17:1154-1156.
7. Dang, Z.C., van Bezooijen, R.L., Karperien, M., Papapoulos, S.E., Löwik, C.W., 2002. Exposure of KS483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J. Bone Miner. Res. 17, 394-405.
8. Davis V.L., Couse J.F., Gray T.K., Korach K.S. Correlation between lowlevels of estrogen receptors and estrogen responsiveness in two rat osteoblast-like cell lines. J. Bone Miner. Res. 1994, 9:983-991.
9. Feng J., Shi Z., Ye Z. Effects of metabolites of the lignans enterolactone and enterodiol on osteoblastic differentiation of MG-63 cells. Biol. Pharm. Bull. 2008, 31:1067-1070.
10. Florian M., Magder S. Estrogen decreases TNF-alpha and oxidized LDL induced apoptosis in endothelial cells. Steroids 2008, 73:47-58.
11. Gori F., Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Khosla S., Riggs B.L. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000, 141:4768-4776.
12. Harris S.A., Tau K.R., Turner R.T., Spelsberg T.C. Estrogens and progestins. Principles of Bone Biology 1996, 507-520. Academic Press, San Diego. J.P. Bilezikian (Ed.).
13. Ip S.W., Weng Y.S., Lin S.Y., Yang M.D., Tang N.Y., Su C.C., Chung J.G. The role of Ca2+ on rhein-induced apoptosis in human cervical cancer Ca Ski cells. Anticancer Res. 2007, 27:379-389.
14. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner. Res. 1998, 13:793-802.
15. Jilka R.L., Weinstein R.S., Parfitt A.M., Manolagas S.C. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J. Bone Miner. Res. 2007, 22:1492-1501.
16. Kallio A., Guo T., Lamminen E., Seppänen J., Kangas L., Väänänen H.K., Härkönen P. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol. Cell. Endocrinol. 2008, 289:38-48.
17. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000, 65:227-251.
18. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen B.S., Katzenellenbogen P.K., Roberson P.K., Weinstein R.S., Jilka R.L., Manlagas S.C. Nongenotropic, sex-nonspecific signalling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104:719-730.
19. Kousteni S., Han L., Chen J.R., Almeida M., Plotkin L., Bellido T., Manolagas S. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 2003, 111:1651-1664.
20. Li, L.Z., Cui, Yi., Zhang, Y.L., Cui, Yo., 2004. Preparative methods of radix anthraquinone derivatives and active components of these derivatives-based drug combination. Chinese Patent ZL10094131.7.
21. Li L.Z., Cui Yo., Cui Yi., Gong H.Y., Zhang Y.L. Synthesis and pharmacological activities of a series of estrogen-rhein hybrid compounds. J. China Pharm. Univ. 2007, 38:6-11.
22. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., Liu Y.X., Yang J., Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol. Cancer Res. 2008, 6:917-928.
23. Lin Y.J., Zhen Y.S. Rhein lysinate suppresses the growth of breast cancer cells and potentiates the inhibitory effect of Taxol in athymic mice. Anticancer Drugs 2009, 20:65-72.
24. Lin Y.J., Zhen Y.Z., Shang B.Y., Zhen Y.S. Rhein lysinate suppresses the growth of tumor cells and increases the anti-tumor activity of Taxol in mice. Am. J. Chin. Med. 2009, 37:923-931.
25. Luo X.H., Liao E.Y. Effects of estriol on the proliferation and differentiation of human osteoblastic MG-63 cells. Endocr. Res. 2003, 29:343-351.
26. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 2000, 21:115-137.
27. Nakashima T., Sasaki H., Tuboi M., Kawakami A., Fyjiyama K., Kiriyama T. Inhibitory effect of glugocorticoid for osteoblast apoptosis induced by activated peripheral blood mononuclear cells. Endocrinology 1998, 139:2032-2040.
28. Neale J.R., Richter N.B., Merten K.E., Taylor K.G., Singh S., Waite L.C., Emery N.K., Smith N.B., Cai J., Pierce W.M. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg. Med. Chem. Lett. 2009, 19:680-683.
29. Oñate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
30. Orme M.W., Labroo V.M. Synthesis of β-estradiol-3-benzoate-17-(succinyl-12A-tetracycline): a potential bone-seeking estrogen. Bioorg. Med. Chem. Lett. 1994, 4:1375-1380.
31. Perillo B., Sasso A., Abbondanza C., Palumbo G. 17beta-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol. Cell. Biol. 2000, 20:2890-2901.
32. Riggs B.L., Khosla S., Melton L.J. Sex steroids and the construction and conservation of adult skeleton. Endocr. Rev. 2002, 23:279-302.
33. Salvatori L., Caporuscio F., Coroniti G., Starace G., Frati L., Russo M.A., Petrangeli E. Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J. Cell. Physiol. 2009, 220:35-44.
34. Schiff R., Massarweh S., Shou J., Osborne C.K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 2003, 9:447S-454S.
35. Shi P., Huang Z., Chen G. Rhein induces apoptosis and cell cycle arrest in human hepatocellular carcinoma BEL-7402 cells. Am. J. Chin. Med. 2008, 36:805-813.
36. Stein G.S., Lian J.B. Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr. Rev. 1993, 14:424-442.
37. Stein G.S., Lian J.B., Owen T.A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 1990, 4:3111-3123.
38. Takeshita A., Yen P.M., Misiti S., Cardona G.R., Liu Y., Chin W.W. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator. Endocrinology 1996, 137:3594-3597.
39. Thirunavukkarasu K., Halladay D.L., Miles R.R., Yang X., Galvin R.J., Chandrasekhar S., Martin T.J., Onyia J.E. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J. Biol. Chem. 2000, 275:25163-25172.
40. Tsushima N., Yabuki M., Harada H., Katsumata T., Kanamaru H., Nakatsuka I., Yamamoto M., Nakatsuka M. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogen-bisphosphonate hybrid compound. J. Pharm. Pharmacol. 2000, 52:27-37.
41. Urayama S., Kawakami A., Nakashima T., Tsuboi M., Yamasaki S., Hida A., Ichinose Y., Nakamura H., Ejima E., Aoyagit-Nakamura T., Migita K., Kawabey-Eguchi K. Effect of vitamin K2 on osteoblast apoptosis: vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J. Lab. Clin. Med. 2000, 136:181-193.
42. Wang L., Mao Y.J., Wang W.J. Inhibitory effect of diacerein on osteoclastic bone destruction and its possible mechanism of action. Yao Xue Xue Bao 2006, 41:555-560.
43. Wang Y., Niu X., Qu Y., Wu J., Zhu Y., Sun W., Li L. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010, 295:110-123.
44. Wang Y., Li L.Z., Zhang Y.L., Zhu Y.Q., Wu J., Sun W.J. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. Mol. Cell. Endocrinol. 2011, 337:43-51.
45. Watson C.S., Gametchu B. Proteins of multiple classes may participate in nongenomic steroid actions. Exp. Biol. Med. (Maywood) 2003, 228:1272-1281.
46. Watson C.S., Bulayeva N.N., Wozniak A.L., Finnerty C.C. Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 2005, 70:364-371.
47. Weinstein R.S., Manolagas S.C. Apoptosis and osteoporosis. Am. J. Med. 2000, 108:153-164.
48. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 1998, 102:274-282.
49. Willson T.M., Charifson P.S., Baxter A.D., Geddie N.G. Bone targeted drugs 1: identification of heterocycles with hydroxyapatite affinity. Bioorg. Med. Chem. Lett. 1996, 6:1043-1046.
50. Yokogawa K. Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, l-Asp-Hexapeptide-Conjugated Estradiol. Biol. Pharm. Bull. 2006, 29:1229-1233.
51. Yokogawa K., Miya K., Sekido T., Higashi Y., Nomura M., Fujisawa R., Morito K., Masamune Y., Waki Y., Kasugai S., Miyamoto K. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001, 142:1228-1233.
52. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann. NY Acad. Sci. 2006, 1068:173-179.
53. Zhang, Y., Touneksti, O., Akerman, B., Goodyer, C., LeBlanc, A., 2001. 17-beta-Estradiol induces an inhibitor of active caspases. J. Neurosci. 21, RC176.
54. Zhang L., Cui Y., Li L.Z. Research on absorbance ability of radix anthraquinone compounds by hydroxyapatite. Acta Acad. Med. CPAF 2008, 17:1048-1050.
55. Zhang L., Jin X., Li L.Z., Zhang Y.L., Tang C.G., Wang Y. The effects of rhein-estrone on the bone mineral density and uterus in ovariectomized rats. Acta Acad. Med. CPAF 2010, 19:841-843.